Sarah Cannon Research Institute | Strategic Alliance Partners

Melissa L. Johnson, MD, expands on the updated data from the POSEIDEN trial, the rationale for investigating the combination, and what these results mean for the treatment of metastatic non–small cell lung cancer.

Melissa L. Johnson, MD, discusses the evolution of frontline treatment in non–small cell lung cancer.

Ribociclib plus endocrine therapy elicited statistically significant progression-free survival and overall survival benefits vs placebo plus endocrine therapy in patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases, including those with liver metastases and multiple metastatic sites.

The frontline combination of tremelimumab plus durvalumab and chemotherapy generated a long-term overall survival benefit in patients with metastatic non–small cell lung cancer.

Erika P. Hamilton, MD, discusses testing used to identify patients with HER2-positive and HER2-low breast cancer.

Erika P. Hamilton, MD, shares how multidisciplinary collaboration between pathologist and breast oncologists is key to staying abreast of not only the classification-actionable HER2 mutations in metastatic breast cancer but also the evolving definition of expression.

Benjamin Garmezy, MD, discussed the positive trajectory of antibody-drug conjugates and immunotherapy in urothelial carcinoma, highlighting the importance of considering individual patient eligibility for treatments like first-line chemotherapy.

HPN328, a novel half-life extended DLL3-targeting T-cell engager, demonstrated clinical activity and tolerability in patients with pretreated small cell lung cancer and other neuroendocrine tumors, according to findings from a phase 1/2 study (NCT04471727).

Erika P. Hamilton, MD, discusses the updated analysis of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative breast cancer.

Updated data from a safety analysis of the phase 3 DESTINY-Breast03 study confirmed the tolerability of trastuzumab deruxtecan among patients with with HER2-positive unresectable or metastatic breast cancer.

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

The novel allogeneic CAR-engineered natural killer cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia and non-Hodgkin lymphoma.

David Spigel, MD, discusses potential upcoming developments in targeted therapies for non–small cell lung cancer.

Investigators hope to address the need for additional treatment options for patients with class II or class III BRAF-altered disease with KIN-2787, a next-generation, orally available, potent, and selective small molecule inhibitor.

The survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly three decades, thanks in large part to scientific discoveries and treatment advances.

Meredith McKean, MD, MPH, discusses the importance of molecular profiling in melanoma.

Meredith McKean, MD, MPH, discusses how the presence of atypical BRAF mutations affects treatment selection in patients with metastatic melanoma, highlighted the ongoing KN-8701 trial, and explained why developments in this space further solidify the importance of broad molecular profiling.

David Spigel, MD, discussed the focus of each presentation, which centered on immunotherapy vs chemoimmunotherapy in the frontline metastatic setting, the surgical perspective of treatment in early-stage NSCLC, best practices for molecular testing, and EGFR- and KRAS-targeted therapies for patients with advanced disease.

One of the reverberating themes of 2021 that should carry into 2022 is the importance of molecular testing.

The shift away from accepting only positive overall survival (OS) data from phase 3 trials as the pathway toward regulatory approval has been the biggest takeaway from 2021 in lung cancer.

Melissa L. Johnson, MD, discusses new drug approvals for EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

Melissa Johnson, MD, discusses highlights from the 2021 ESMO Congress.

Dr. Johnson discusses the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant non–small cell lung cancer, and where the combination could be used in practice pending further positive study results.

Melissa L. Johnson, MD, discusses the emergence of datopotamab deruxtecan in non–small cell lung cancer with actionable genomic alterations.

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors.

Erika P. Hamilton, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.

Selective estrogen receptor degraders and antibody-drug conjugates are not only broadening the armamentarium in breast cancer but are demonstrating increasing utility across subtypes and in underserved populations, such as those with HER2-low disease, explained Erika P. Hamilton, MD.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.